Chronic Central Serous Chorioretinopathy
Conditions
Brief summary
The aim of the study is to determine the efficacy and safety of treatment with the drug eplerenone in patients with chronic central serous chorioretinopathy.
Interventions
Sponsors
Semmelweis University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Chronic central serous chorioretinopathy (CSCR) with persistent subretinal fluid on OCT for more than 3 months after initial presentation . * Written informed consent
Exclusion criteria
* Persons with impaired decision-making ability. * Pregnant women or who are actively trying to conceive. * Additional eye disease affecting the macula or posterior retina. * Creatinine clearance \< 50 ml/min * Hyperkalemia \> 5 mmol/l * Serum creatinine \> 2 mg/dl in men or \> 1.8 mg/dl in women * Treatment with potassium sparing agents or potassium * Treatment with any other drugs known to cause interaction with eplerenone * Microalbuminuria in patients with type 2 diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resolution of sub-retinal fluid measured by optical coherence tomography (OCT). | 6 months |
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability. | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Changes in macular volume at baseline, during and after the treatment with eplerenone. | 6 months |
| Changes in visual acuity at baseline measured on Early Treatment of Diabetic Retinopathy Study (ETDRS) chart, during and after the treatment with eplerenone. | 6 months |
| Changes in choroideal thickness at baseline measured by OCT, during and after the treatment with eplerenone in both eyes. | 6 months |
Countries
Hungary
Outcome results
None listed